Advertisement
Advertisement
U.S. markets open in 1 hour 9 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Genmab A/S (GMAB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.13-0.08 (-0.23%)
At close: 04:00PM EDT
35.11 -0.02 (-0.06%)
Pre-Market: 07:50AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close35.21
Open35.49
Bid34.93 x 1800
Ask35.05 x 800
Day's Range35.00 - 35.58
52 Week Range26.19 - 49.07
Volume621,044
Avg. Volume666,462
Market Cap22.949B
Beta (5Y Monthly)0.64
PE Ratio (TTM)71.69
EPS (TTM)0.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GMAB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genmab A/S
    Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    Genmab Improves Its 2022 Financial Guidance

    Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on May 11, 2022. The improved guidance is driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the positive net foreign exchange impact of the strong U.S. Dollar. Genmab expects its 2022 revenue to be in the range of DKK 12,000 – 13,000 million, an increase to th

  • GlobeNewswire

    Transactions in connection with share buy-back program

    Company Announcement COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than August 31, 2022 and comprises up to 370,000 shares. The following transactions were executed under the program from August 1, 2022 to August 5, 2022: No.

  • Benzinga

    Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates

    Genmab A/S (NASDAQ: GMAB) and BioNTech SE (NASDAQ: BNTX) have expanded their global strategic collaboration to develop and commercialize novel cancer immunotherapies. Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. The expanded collaboration will leverage Genmab's HexaBody technology platform. The first monospecific antibody candidate, GEN1053/BNT313, is expected to enter cli

Advertisement
Advertisement